Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites

Rhea-AI Summary

Vivos Inc. (OTCQB: RDGL) plans two new production sites to diversify manufacturing for its RadioGel® and IsoPet® therapies, targeting one U.S. facility and one international site operational in 2026.

The company signed a production-space contract at APEL in Richland, Washington; equipment has been ordered, installation is underway, and licensing applications have been submitted. Vivos will continue with its current Texas contract manufacturer through Q2 2026 while pursuing talks with radiopharmaceutical producers in India to reduce shipping costs and expand global access.

Positive

• Signed production-space contract at APEL in Richland, Washington
• Manufacturing equipment ordered and installation underway for automated production
• Target: two facilities (one U.S., one international) planned to be operational in 2026
• International footprint aimed to reduce shipping costs and expand market access

Negative

• Licensing applications submitted; regulatory approval still pending
• Current contract manufacturing continues through Q2 2026, delaying full internal control
• International production talks in India are ongoing and not finalized

Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel^® Radionuclide Therapy^™ (PRnT^™) is preparing to open two new production facilities.

Previous corporate filings have included risk factors regarding the Company’s continued use of a single production site. For the past two years, the Company has been assessing alternate facilities. The Company’s strategic target is to have one domestic production facility, in which the Company will be the manufacturer of record, and one international production facility operational in 2026. These facilities will produce the Y-90 phosphate particles and mix with sterile hydrogel to produce individual patient doses. The Company will continue production with its existing contract manufacturer in Texas through Q2 of 2026.

Vivos has signed a contract for production space at the Applied Process Engineering Laboratory (APEL) in Richland, Washington. Manufacturing equipment has been ordered, installation is underway, and required licensing applications have been submitted. This facility will be the cornerstone of the Company’s future automated production development, positioning Vivos to support higher production volumes, improved efficiency, and long-term expansion. APEL will also serve as a production site for the Company’s Peltier and Duncan Chillers.

In parallel, the Company is engaged in discussions with experienced radiopharmaceutical contract manufacturers in India regarding the establishment of an international production facility. The Company anticipates that one of these facilities could be operational by the end of 2026. An international production footprint is expected to significantly reduce shipping costs and logistical complexity, expanding access to international markets and supporting the global growth of RadioGel^® (human) and IsoPet^® (veterinary) therapies.

CONTACTS:

Mike Korenko, ScD	Brad Weeks
CEO, Vivos Inc	President, Vivos Inc
mkorenko@radiogel.com	Brad.Weeks@vivosinc.com

Follow Vivos Inc. on X (Twitter): @VivosIncUSA

Learn more about RadioGel^® and IsoPet^® at www.VivosInc.com

About Vivos Inc.
Vivos Inc. is a clinical-stage medical device company developing RadioGel^®, a precision radiotherapy hydrogel for human and veterinary oncology applications. IsoPet^® is commercially available for veterinary use in certified clinics nationwide.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks are detailed in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

FAQ

What did Vivos (RDGL) announce about new production facilities on February 17, 2026?

Vivos plans one U.S. and one international production facility, targeting operations in 2026. According to the company, it signed space at APEL in Richland, ordered equipment, began installation, and submitted licensing applications while keeping Texas manufacturing through Q2 2026.

Where will Vivos (RDGL) locate its domestic production site and what is its status?

The domestic site is at APEL in Richland, Washington, with equipment ordered and installation begun. According to the company, licensing applications have been submitted and the site will support automated production and chillers.

How long will Vivos (RDGL) continue using its Texas contract manufacturer?

Vivos will continue production with its existing Texas contract manufacturer through Q2 2026. According to the company, the transition plan keeps current manufacturing active while new facilities are established.

What is Vivos (RDGL) doing to establish international manufacturing in 2026?

Vivos is engaged in discussions with experienced radiopharmaceutical contract manufacturers in India to establish an international site. According to the company, one facility could be operational by the end of 2026 to reduce shipping and logistics.

What products will the new Vivos (RDGL) facilities produce and how will they be used?

The facilities will produce Y-90 phosphate particles and mix them with sterile hydrogel to create patient doses. According to the company, this supports RadioGel (human) and IsoPet (veterinary) therapies and higher production volumes.

How might Vivos (RDGL)'s new facilities affect international access and costs?

An international production footprint is expected to significantly reduce shipping costs and simplify logistics for global distribution. According to the company, this will expand access to RadioGel and IsoPet therapies in international markets.